SUPERIORITY OF POST-RADIOTHERAPY ADJUVANT CHEMOTHERAPY WITH CCNU, PROCARBAZINE, AND VINCRISTINE (PCV) OVER BCNU FOR ANAPLASTIC GLIOMAS - NCOG-6G61 FINAL REPORT

被引：327

作者：

LEVIN, VA

SILVER, P

HANNIGAN, J

WARA, WM

GUTIN, PH

DAVIS, RL

WILSON, CB

机构：

[1] UNIV CALIF SAN FRANCISCO,SCH MED,BRAIN TUMOR RES CTR,DEPT NEUROL SURG,SAN FRANCISCO,CA 94143

[2] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT RADIAT ONCOL,SAN FRANCISCO,CA 94143

[3] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PATHOL NEUROPATHOL,SAN FRANCISCO,CA 94143

[4] NO CALIF ONCOL GRP,BELMONT,CA 94002

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1990年 / 18卷 / 02期

关键词：

BCNU; CCNU; Chemotherapy; Glioblastoma multiforme; Glioma; PCV; Procarbazine;

D O I：

10.1016/0360-3016(90)90096-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Data from Northern California Oncology Group protocol 6G61, which was closed in February 1983, were reanalyzed in December 1988. The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas. PCV produced longer survival and time to tumor progression than BCNU for both histologic groups, although the difference was statistically significant only for the anaplastic gliomas. With PCV treatment, time to progression and survival doubled for anaplastic glioma patients in the 50th and 25th percentiles. © 1990.

引用

页码：321 / 324

页数：4

共 16 条

[1]

CHANG CH, 1983, CANCER, V52, P997, DOI 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO

[2]

2-2

[3]

COX DR, 1972, J R STAT SOC B, V34, P187

[4]

Eyre H J, 1983, J Neurooncol, V1, P171, DOI 10.1007/BF00165600

[5]

GREEN SB, 1983, CANCER TREAT REP, V67, P121

[6]

LEVIN VA, 1986, CANCER TREAT REP, V70, P739

[7] PHASE-III COMPARISON OF BCNU, HYDROXYUREA, AND RADIATION-THERAPY TO BCNU AND RADIATION-THERAPY FOR TREATMENT OF PRIMARY MALIGNANT GLIOMAS [J].

LEVIN, VA ;

WILSON, CB ;

DAVIS, R ;

WARA, WM ;

PISCHER, TL ;

IRWIN, L .

JOURNAL OF NEUROSURGERY, 1979, 51 (04) :526-532

[8] PHASE-III COMPARISON OF BCNU AND THE COMBINATION OF PROCARBAZINE, CCNU, AND VINCRISTINE ADMINISTERED AFTER RADIOTHERAPY WITH HYDROXYUREA FOR MALIGNANT GLIOMAS [J].

LEVIN, VA ;

WARA, WM ;

DAVIS, RL ;

VESTNYS, P ;

RESSER, KJ ;

YATSKO, K ;

NUTIK, S ;

GUTIN, PH ;

WILSON, CB .

JOURNAL OF NEUROSURGERY, 1985, 63 (02) :218-223

[9]

LEVIN VA, 1989, CANCER PRINCIPLES PR, P1557

[10] A RANDOMIZED COMPARISON OF MISONIDAZOLE SENSITIZED RADIOTHERAPY PLUS BCNU AND RADIOTHERAPY PLUS BCNU FOR TREATMENT OF MALIGNANT GLIOMA AFTER SURGERY - PRELIMINARY-RESULTS OF AN RTOG STUDY [J].

NELSON, DF ;

SCHOENFELD, D ;

WEINSTEIN, AS ;

NELSON, JS ;

WASSERMAN, T ;

GOODMAN, RL ;

CARABELL, S .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1983, 9 (08) :1143-1151

← 1 2 →